Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)

 描述(申请人提供)：这个癌症纳米技术卓越转化诊断中心(CCNE-TD)汇集了来自斯坦福大学和麻省理工学院的科学家和医生，共同应对癌症早期检测、图像引导活检、监测治疗反应和早期区分侵袭性和惰性疾病的严峻挑战。这项研究提案的核心是我们的愿景，即体外诊断与体内分子成像结合使用可以显著影响未来癌症患者的治疗。此外，我们认为，纳米技术可以通过纳米传感器进行体外诊断，也可以通过用于分子成像的纳米颗粒进行体内诊断。我们将研究的两种主要癌症是肺癌和前列腺癌。对于肺癌，我们将应用我们的技术进行早期发现和监测治疗反应。对于前列腺癌，我们将使用我们的技术来改进图像引导活检，区分早期侵袭性癌症和惰性癌症，并监测治疗反应。我们已经组建了一支高度跨学科的科学家团队，他们拥有高度协同的专业知识和悠久的合作历史。我们将利用我们已经创办的几家小公司的大量资源，并计划进一步将我们最有前途的技术商业化。项目1的重点是开发新型的癌症触发的自组装和拆解纳米粒子，用于正电子发射断层扫描(PET)显示肺部肿瘤及其对化疗的反应。项目2的重点是利用磁性纳米技术进行血液生物标记物、浓缩后循环肿瘤细胞的单细胞分析以及血源性肺癌标记物的综合分析。项目3的重点是细胞外小泡的生物物理分析及其在前列腺癌发生中的作用。项目4的重点是前列腺癌的分子成像，包括用于组合光声/超声成像的定向纳米气泡和用于光声成像的自组装纳米颗粒。管理核心将促进我们迈向里程碑的进展，核心1将为纳米表征和制造提供资源，核心2将通过将我们的纳米技术与现有患者样本以及正在进行的/新的临床试验联系起来，促进临床翻译。对临床样本和研究的杠杆访问包括几个大型肺癌临床试验(MD Anderson肺癌早期检测月球计划)、前列腺癌(由金丝雀基金会运行的前列腺癌主动监测研究(PASS))，以及斯坦福-谷歌[X]-杜克大学基线研究，以研究10,000人从健康到疾病的转变，该研究于2015年启动。随着我们高度互动和有凝聚力的计划专注于开发和验证用于癌症早期检测和预测的纳米技术、改进的图像引导活检和抗癌治疗反应，我们将想象、发明、创新和翻译。

 DESCRIPTION (provided by applicant): This Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD) brings together scientists and physicians from Stanford University and the Massachusetts Institute of Technology to tackle the grand challenges of cancer early detection, image guided biopsy, monitoring response to therapy and early discrimination of aggressive vs. indolent disease. This research proposal is centered on our vision that in vitro diagnostics used in conjunction with in vivo molecular imaging can markedly impact future cancer patient management. Furthermore, we believe that nanotechnology can significantly advance both in vitro diagnostics through nanosensors, and in vivo diagnostics through nanoparticles for molecular imaging. The two major cancers that we will study are lung and prostate cancer. For lung cancer we will apply our technologies for early detection and to monitor response to therapy. For prostate cancer we will use our technologies to improve image guided biopsy, distinguish early aggressive vs. indolent cancers, and monitor response to therapy. We have assembled a highly interdisciplinary team of scientists with highly synergistic expertise and a long collaboration history. We will utilize significant resources at several small companies we have started and plan to further commercialize our most promising technologies. Project 1 focuses on the development of novel cancer triggered self-assembling and disassembling nanoparticles for positron emission tomography (PET) visualization of lung tumors and their response to chemotherapy. Project 2 focuses on the use of magneto- nanotechnology for blood biomarkers, single cell analysis of circulating tumor cells after enrichment and comprehensive analyses of blood-borne lung cancer markers. Project 3 focuses on the biophysical analysis of extracellular vesicles and their role in prostate cancer oncogenesis. Project 4 focuses on molecular imaging of prostate cancer with targeted nanobubbles for combined photoacoustic/ultrasound imaging and self-assembling nanoparticles for photoacoustic imaging. The Administrative Core will facilitate progress towards our milestones, Core 1 will provide resources for nano characterization and fabrication, and Core 2 will facilitate clinical translation by linking our nanotechnologies to existing patient samples, ad ongoing/new clinical trials. Leveraged access to clinical samples and studies include several large clinical trials for lung cancer (MD Anderson Lung Cancer Early Detection Moonshots Program), prostate cancer (The Prostate Active Surveillance Study (PASS) run by the Canary Foundation), and the Stanford-Google[X]- Duke baseline study to study the transition from health to illness in 10,000 individuals being launched in 2015. With our highly interactive and cohesive program focused on developing and validating nanotechnology for earlier cancer detection and prognostication, improved image guided biopsies, anti- cancer therapy response, we will imagine, invent, innovate, and translate.